

118TH CONGRESS
1ST SESSION

H. R. 3703

To direct the Comptroller General of the United States to conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce certain medical countermeasures in the event of a public health emergency, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 25, 2023

Mr. LATTA (for himself and Ms. KELLY of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To direct the Comptroller General of the United States to conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce certain medical countermeasures in the event of a public health emergency, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Helping Evaluate Ap-
5 propriate Logistical Infrastructure for National Govern-

1 ment Response Act of 2023” or the “HEALING Response
2 Act of 2023”.

3 **SEC. 2. GAO REVIEW OF HHS EFFORTS TO ENSURE RAPID**
4 **PRODUCTION OF CERTAIN MEDICAL COUN-**
5 **TERMEASURES IN CASE OF A PUBLIC**
6 **HEALTH EMERGENCY.**

7 (a) IN GENERAL.—Not later than 1 year after the
8 date of the enactment of this Act, the Comptroller General
9 of the United States shall conduct and complete a review
10 examining the efforts of the Secretary of Health and
11 Human Services to ensure that the United States is pre-
12 pared to rapidly produce qualified countermeasures (as de-
13 fined in section 319F–1 of the Public Health Service Act
14 (42 U.S.C. 247d–6a)) in the event of a public health emer-
15 gency declared under section 319 of the Public Health
16 Service Act (42 U.S.C. 274d).

17 (b) CONTENTS.—The review conducted under sub-
18 section (a) shall include a review of—

19 (1) the efforts described in such subsection, in-
20 cluding the Secretary’s efforts to transition from the
21 Centers for Innovation and Advanced Drug Manu-
22 facturing program to any new efforts, including the
23 National Biopharmaceutical Manufacturing Partner-
24 ship and Industrial Base Expansion Connect;

1 (2) the progress made toward the implementa-
2 tion of such efforts; and

3 (3) the planning within the Department of
4 Health and Human Services to assess risks and
5 challenges associated with advanced development
6 and manufacturing of qualified countermeasures.

7 (c) REPORT TO CONGRESS.—Not later than 1 year
8 after completing the review under subsection (a), the
9 Comptroller General of the United States shall submit to
10 the Congress a report containing—

11 (1) the results of the review; and

12 (2) the Comptroller General’s recommendations
13 for ensuring that the United States is prepared to
14 rapidly produce qualified countermeasures in the
15 event of a public health emergency.

○